WINDOWS OF OPPORTUNITY FOR THE PHARMACOLOGICAL TREATMENT OF COVID-19

Abstract

Even after almost 8 months after the COVID-19 Pandemic we do not have a specific treatment for the virus. We have understood the effects of the virus better so that we can plan to use this knowledge to create windows of opportunity for the pharmacological treatment of COVID-19. To put it in a nutshell, HCQS / Chloroquine (to prevent entry of virus), Dexamethasone to douse the angry Cytokine storm (inhaled Budesonide in early asymptomatic / symptomatic stages). Use of Heparin after realizing the role of microthrombosis in Hypoxia has reduced unnecessary use of ventilator which has translated into reduced mortality. Role of Remdesivir (in preventing the stabilization of viral RNA) and Tocilizumab (in dousing the destructive activation of IL-6) has been questioned in recent studies. The role of Plasma therapy is still being evaluated. The vaccine is not yet ready for use in general population. As of now we are relying on use of masks, hand hygiene and social distancing for prevention of spread. windows of opportunity for the pharmacological treatment of covid-19 are still open.